Requires pharmacy benefits manager compensation to be based on bona fide service fee.
S4205 would amend New Jersey law governing pharmacy benefits managers (PBMs) by requiring that compensation paid to a PBM, or to a PBM affiliate, for administering prescription drug benefits be structured only as a bona fide service fee. The bill defines that fee as a flat-dollar amount reflecting fair market value for a specific, itemized service actually performed on behalf of the purchaser, and it must not be passed through to covered persons. It also bars compensation arrangements that function as commissions or that are tied to drug prices, rebates, discounts, formulary placement, referral volume, or other prohibited methodologies.
The bill also adds reporting and documentation requirements for carriers and PBMs in rate filings. Carriers using PBMs must treat PBM compensation as an administrative cost rather than a benefit under the health plan, and they may count only amounts actually paid to pharmacies or pharmacists as incurred claims. Rate filings would need an actuary’s memorandum explaining the PBM compensation calculation, along with supporting records the Department of Banking and Insurance deems necessary. Carriers and PBMs would each be required to provide records and documentation to help the department verify compliance.
If enacted, S4205 would amend P.L.2023, c.107 and tighten state oversight of PBM compensation practices in the health insurance market. It would affect carriers, PBMs, pharmacy services administrative organizations, and their affiliates by limiting how they may be paid and by changing how PBM-related costs are treated in loss ratio and rate filings. The Commissioner of Banking and Insurance would gain authority to determine fair market value for bona fide service fees and to require supporting documentation and anticipatory administrative action before the effective date.
The bill’s text and structure suggest a reform-oriented approach aimed at increasing transparency and limiting compensation practices viewed as potentially distorting drug costs or insurance pricing. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or formal support/opposition in the available record. Based on the bill’s design, the likely general sentiment is favorable among proponents of PBM reform and scrutiny of prescription drug middlemen, with concern from industry stakeholders that the restrictions could reduce flexibility in contracting and compensation.
The main points of contention are likely to center on whether PBM compensation should be restricted to flat, bona fide service fees and whether the Commissioner of Banking and Insurance should have broad discretion to define fair market value and prohibit other methodologies. PBMs and affiliated entities may object to the ban on commission-like structures and compensation tied to rebates, discounts, or formulary decisions, while insurers and consumer advocates may support the bill as a way to curb opaque pricing and align incentives. Another likely dispute is the administrative burden of expanded documentation, actuarial memoranda, and record production requirements for carriers and PBMs.